Physician profile
Lyle Harrison
NPI 1750453361
$1,780.76
in general payments reported to CMS, 2019-2025
41 companies · $659 in 2025
The $659 reported for 2025 was more than what 79% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $17.27 · 2021: $169 · 2022: $86.75 · 2023: $62.40 · 2024: $589 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $236.73 | 2019-2024 | Lynparza |
| Janssen Biotech, INC. | $159.82 | 2019-2025 | Rybrevant, Erleada, Akeega |
| Takeda Pharmaceuticals U.S.A., INC. | $107.04 | 2024-2025 | Alunbrig, Fruzaqla, Iclusig |
| Novocure INC. | $92.27 | 2021-2025 | Optune Lua (Novottf-200t), Optune |
| Abbvie INC. | $80.74 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $78.09 | 2022-2024 | Camzyos |
| Glaxosmithkline, LLC. | $72.75 | 2024-2025 | Ojjaara |
| Tersera Therapeutics LLC | $65.89 | 2024-2025 | Zoladex |
| Sumitomo Pharma America, INC. | $65.29 | 2024-2025 | Orgovyx |
| Novartis Pharmaceuticals Corporation | $56.53 | 2024-2025 | |
| Lilly USA, LLC | $55.92 | 2024-2025 | Verzenio |
| Incyte Corporation | $55.69 | 2024-2025 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $41.80 | 2025 | Libtayo |
| Merck Sharp & Dohme LLC | $36.96 | 2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $36.51 | 2019-2025 | Enhertu |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyle Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.